A clinical trial of a bivalent booster is now underway

Moderna announced that the first participant in the Phase II clinical trial of the candidate for a bivalent booster dose for the Omikron variant (mRNA-1273.214) has been vaccinated. This preparation is a combination of a candidate Omikron variant specific booster (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273).

As a continuation of the previous study, the immunogenicity, safety and reactogenicity of mRNA-1273.214 as a single booster dose in adults 18 years and older who previously received a priming of mRNA-1273 (two doses) and a boost of mRNA-1273 will be assessed (50 µg), with a booster dose at least three months ago. Moderna plans to involve approximately 375 people in the study, which will be conducted in 20 centers in the United States.

In addition, an Omikron variant-specific candidate (mRNA-1273.529) booster is currently being analyzed in a Phase II trial in the United States. In parallel, in collaboration with the National Institute for Health Research (NIHR), Moderna is conducting a Phase III clinical trial in the UK to evaluate mRNA-1273.529. The mRNA-1273.214 preparation in this study is expected to start soon.

press info